Subscriber access provided by University of Sussex Library
Article
In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract Under Fed and Fasted Conditions Duxin Sun, Jason R. Baker, Bo Wen, Ann Frances, Huixia Zhang, Alex Yu, Ting Zhao, Yasuhiro Tsume, Manjunath Pai, Barry Bleske, Xinyuan Zhang, R. Lionberger, Allen Lee, Gordon Amidon, William L. Hasler, and Mark Koenigsknecht Mol. Pharmaceutics, Just Accepted Manuscript • DOI: 10.1021/acs.molpharmaceut.7b00425 • Publication Date (Web): 22 Sep 2017 Downloaded from http://pubs.acs.org on September 24, 2017
Just Accepted “Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.
Molecular Pharmaceutics is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.
Page 1 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40
Molecular Pharmaceutics
In Vivo Dissolution and Systemic Absorption of Immediate Release Ibuprofen in Human Gastrointestinal Tract Under Fed and Fasted Conditions Mark J. Koenigsknecht1, Jason R. Baker2, Bo Wen1, Ann Frances1, Huixia Zhang1, Alex Yu1, Ting Zhao1, Yasuhiro Tsume1, Manjunath P. Pai3, Barry E Bleske4, Xinyuan Zhang5§, Robert Lionberger5§, Allen Lee2, Gordon L. Amidon1, William L. Hasler2*, Duxin Sun1* Affiliations 1Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, USA 2Department
of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48109, USA
3Department
of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, USA
4 Department
of Pharmacy Practice and Administrative Sciences, College of Pharmacy, University of New Mexico, Albuquerque, New Mexico, 87120, USA
5Office
of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland 20993, USA
§Disclaimer:
The views expressed in this article are those of the authors and not necessarily those of the Food and Drug Administration (FDA).
*Corresponding
authors:
Duxin Sun, Ph.D., Professor, Department of Pharmaceutical Sciences, College of Pharmacy. University of Michigan, Room 3353, Building 520,1600 Huron Parkway, Ann Arbor, Michigan 48105. Phone: 734-615-8740, Email:
[email protected] William L. Hasler, M.D., Professor, Department of Internal Medicine, Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan 48109. Phone: 734936-4780, Email:
[email protected] ACS Paragon Plus Environment
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
41
Page 2 of 32
Graphical Abstract:
42 43
Abstract:
44
Purpose: In vivo drug dissolution in the gastrointestinal (GI) tract is largely
45
unmeasured. The purpose of this clinical study was to evaluate the in vivo drug
46
dissolution and systemic absorption of the BCS Class IIa drug ibuprofen under fed
47
and fasted conditions by direct sampling of stomach and small intestinal luminal
48
content. Expanding current knowledge of drug dissolution in vivo will help to
49
establish physiologically relevant in vitro models predictive of drug dissolution.
50 51
Methods: A multi-lumen GI catheter was orally inserted into the GI tract of healthy
52
human subjects. Subjects received a single oral dose of ibuprofen (800 mg tablet)
53
with 250 mL of water under fasting and fed conditions. The GI catheter facilitated
54
collection of GI fluid from the stomach, duodenum, and jejunum. Ibuprofen
55
concentration in GI fluid supernatant and plasma was determined by LC-MS/MS.
56 57
Results: A total of 23 subjects completed the study, with 11 subjects returning for
58
an additional study visit (a total of 34 completed study visits). The subjects were
ACS Paragon Plus Environment
1
Page 3 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
59
primarily white (61%), male (65%) with an average age of mean of 30 years. The
60
subjects had a median [minutes, max] weight of 79 [52, 123] kg and body mass
61
index of 25.7 [19.4, 37.7] kg/m2. Ibuprofen plasma levels were higher under fasted
62
conditions and remained detectable for 28 hours under both conditions. The AUC0-24
63
and Cmax were lower in fed subjects vs. fasted subjects and Tmax was delayed in fed
64
subjects vs. fasted subjects. Ibuprofen was detected immediately after ingestion in
65
the stomach under fasting and fed conditions until 7 hours after dosing. Higher
66
levels of ibuprofen were detected in the small intestine soon after dosing in fasted
67
subjects compared to fed. In contrast to plasma drug concentration, overall gastric
68
concentrations remained higher under fed conditions due to increased gastric pH vs.
69
fasting condition. The gastric pH increased to near neutrality after feeding before
70
decreasing to acidic levels after 7 hours.
71 72
Conclusions: Induction of the fed state reduced systemic levels but increased
73
gastric levels of ibuprofen, which suggest slow gastric emptying and transit
74
dominate effect for plasma drug concentration. High levels of ibuprofen in stomach
75
and small intestine 7 hours post dosing was an unexpected finding. Future work is
76
needed to better understand the role of various GI parameters, such as motility and
77
gastric emptying, on systemic ibuprofen levels in order to improve in vitro
78
predictive models.
79 80
Key Words:
81
Ibuprofen; in vivo dissolution; pharmacokinetics; immediate release; local
ACS Paragon Plus Environment
2
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
82
Page 4 of 32
gastrointestinal concentration; clinical study
83 84
List of abbreviations:
85
Gastrointestinal (GI), biopharmaceutical classification system (BCS), nonsteroidal
86
anti-inflammatory drug (NSAIDs), Food and Drug Administration (FDA).
87 88 89
Introduction: Designing oral drug formulations with predictable gastrointestinal (GI)
90
absorption profiles is a major objective during drug development. Understanding
91
the dissolution properties of oral formulations using in vitro systems can support
92
this endeavor. Current in vitro models are useful for in vivo prediction of absorption
93
of high solubility drugs. In contrast the absorption of low solubility drugs with high
94
GI permeability, referred to as biopharmaceutical classification system (BCS) II
95
drugs, are especially difficult to predict1, 2. This prediction problem arises from the
96
inability to optimally mimic the dynamic physiologic parameters such as pH,
97
buffering conditions, and shifting GI volumes that impart changes dissolution and
98
absorption of BCS II drugs in the GI tract. Designing a predictive model that is able
99
to address this complex drug-GI behavior may play a major role in drug
100
development. Importantly, such a system has the potential to help qualify waivers
101
of bioavailability and bioequivalence studies for BCS II drugs during generic drug
102
development.
103 104
Currently there are very limited data available analyzing in vivo BCS II drug dissolution and dosage form performance in the GI tract, however recent studies by
ACS Paragon Plus Environment
3
Page 5 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
105
Hens et al. and Van Den Abeele et al. have begun to shed light on drug dissolution
106
and absorption of weakly acidic BCS II drugs3-5. Drug absorption in the GI tract is a
107
complex process that remains to be fully elucidated. Constructing a comprehensive
108
translational model requires clinical measurement of GI variables such as pH, buffer
109
capacity, motility, etc. in order to develop better in vitro models. The goal of this
110
clinical study was to obtain in vivo drug dissolution of BCS Class IIa drug ibuprofen
111
in the GI tract in fed and fasted conditions and correlate with systemic drug
112
concentration. We chose to evaluate a model BCS IIa drug, ibuprofen, one of the
113
most commonly used nonsteroidal anti-inflammatory drug (NSAIDs) to treat acute
114
pain, fever, and inflammation6.
115
The potential benefits of ibuprofen are hampered by side-effects7.
116
Specifically, the chronic use of NSAIDs like ibuprofen is associated with GI adverse
117
events such as gastroduodenal ulceration8. This adverse event occurs due to topical
118
epithelial irritant effects, suppression of GI prostaglandin synthesis, alteration of
119
local GI blood flow, and interference of injury repair mechanisms. To improve GI
120
tolerability, ibuprofen is often taken with food9. Food can delay the rate of ibuprofen
121
absorption and lower its pharmacological effects10. While we understand the effect
122
food has on plasma levels we have yet to understand the effect of food on local GI
123
ibuprofen concentrations.
124
In this study a novel multi-lumen GI catheter was orally placed into the
125
stomach and small intestine of healthy human volunteers to obtain in vivo samples
126
of the GI tract after dosage of an ibuprofen tablet. This study was performed in
127
volunteers under both fed and fasted conditions in order to characterize in vivo drug
ACS Paragon Plus Environment
4
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 6 of 32
128
disintegration and dissolution under each condition. Corresponding plasma samples
129
and GI fluid samples were collected for seven hours following study drug
130
administration. The concentration of ibuprofen in plasma and GI fluid supernatant
131
was determined via LC-MS/MS and correlated with the human physiology data
132
(such as pH) to better understand the effect of food on drug absorption. Correlating
133
in vivo drug concentrations with GI physiology data under fasting and fed conditions
134
from healthy subjects will help support mechanistic absorption model development
135
in the future. This information may also be helpful to improve our understanding of
136
local ibuprofen concentrations that may influence gastroduodenal ulceration with
137
NSAIDs use.
138 139
Methods:
140
Ethics Statement
141
Samples collected in this study were part of clinical trial NCT02806869. The
142
institutional review boards at the University of Michigan (IRBMED, protocol number
143
HUM00085066) and the Department of Health and Human Services, Food and Drug
144
Administration (Research Involving Human Subjects Committee/RIHSC, protocol
145
number14-029D) both approved the study protocol. All subjects provided written
146
informed consent in order to participate. The study was carried out accordance with
147
the protocol, International Conference on Harmonization Good Clinical Practice
148
guidelines, and applicable local regulatory requirements.
149 150
Ibuprofen Formulation
ACS Paragon Plus Environment
5
Page 7 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
151
Ibuprofen tablets (800 mg) were purchased from Dr. Reddy’s Laboratories
152
(Shreveport, LA). The ibuprofen tablet was administered with approximately 250
153
mL of water, actual volumes of water consumed for each subject is listed in
154
Supplemental Table 1. The study drug was dispensed by the Investigational Drug
155
Service (IDS) at the University of Michigan.
156 157
Catheter Design
158
A customized multi-lumen catheter was manufactured by Mui Scientific.
159
(Mississauga, ON, Canada). The catheter was 292 cm long and consisted of four
160
independent aspiration ports located 30-20 cm apart and 16 manometry ports
161
located proximal to the aspiration ports. The outer diameter of the catheter was 3.3
162
mm while the single lumen tubes used for aspiration had an inner diameter of 1.2
163
mm. Additionally, the catheter had a channel to fit a guidewire (0.035 in x 450 cm,
164
Boston Scientific, Marlborough, MA) as well as a channel connected to a balloon that
165
could be filled with 7 mL of water to assist in catheter placement. Finally, the end of
166
the catheter was weighted with 7.75 grams of tungsten weights.
167 168 169
Inclusion and Exclusion Criteria for the Study Male and female healthy human volunteers between the ages of 18 and 55
170
were eligible for inclusion in the study. All subjects completed a physical exam and
171
had their previous medical history reviewed by the study physician to confirm the
172
subjects were healthy volunteers able to participate in the study. All subjects
173
enrolled in the study had normal values for the following laboratory tests: vital
ACS Paragon Plus Environment
6
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 8 of 32
174
signs, electrocardiogram (ECG), urine drug screen, serum pregnancy test (for
175
women of child-bearing potential), comprehensive metabolic panel, complete blood
176
count with platelet and differential, and lactate dehydrogenase. There were no
177
exclusionary criteria in regards to BMI, however all tests listed above had to be in
178
normal range and the subject had to overall be deemed healthy by the study
179
physician.
180
Exclusionary criteria for the study were as follows: Adults unable to consent
181
for themselves or mentally incapacitated; prisoners; significant clinical illness
182
within 3 weeks prior to screening; use of concomitant medications within 2 weeks
183
prior to receiving study drug, including but not limited to prescription drugs, herbal
184
and dietary supplements, over the counter medications, and vitamins (oral
185
contraceptive was permitted); received an investigational drug within 60 days prior
186
to receiving the study drug; history of gastrointestinal surgery; surgery within the
187
past 3 months; history of allergy to ibuprofen or other non-steroidal anti-
188
inflammatory drugs (NSAIDs); pregnant or lactating females; history of severe
189
allergic diseases including drug allergies, with the exception of seasonal allergies;
190
history of drug addiction or alcohol abuse within the past 12 months; any clinically
191
significant abnormal lab values during screening’ any other factor, condition, or
192
disease, including, but not limited to, cardiovascular, renal, hepatic, or
193
gastrointestinal disorders that may, in the opinion of the investigator, jeopardize the
194
safety of the patient or impact the validity of the study results.
195 196
Study Procedure
ACS Paragon Plus Environment
7
Page 9 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
197
Molecular Pharmaceutics
All clinical procedures were performed at the Michigan Clinical Research
198
Unit (MCRU) or the Medical Procedures Unit (MPU) in the University of Michigan
199
hospital. The subjects were instructed to fast beginning 13 hours prior to dosing and
200
to avoid consuming water for 10 hours prior to dosing. Upon arrival a physical exam
201
was performed by the study doctor to ensure the health of the subject prior to the GI
202
catheter insertion procedure. The multi-lumen GI catheter was orally inserted into
203
the GI tract of the subject under the supervision of the study doctor. Lubricating jelly
204
was applied to the GI catheter prior to insertion. To lessen the gag reflex, subjects
205
received a topical anesthetic (1 mL of 4% lidocaine) before the catheter insertion.
206
Once the catheter was swallowed, catheter placement was continued under
207
abdominal fluoroscopy to ensure proper positioning in the GI tract. When catheter
208
placement was completed the GI catheter was secured to the cheek of the subject
209
using medical tape. The subject remained in bed for one hour while the GI tube was
210
equilibrated to the manometry instrument, then for 3-5 hours while baseline GI
211
motility data was collected. Additionally, GI motility was measured continuously for
212
7 hours following study drug administration. The rate of water perfused into the
213
subject to measure motility was approximately 100 mL per hour for the 11-13 hours
214
that motility was recorded.
215
Prior to study drug administration, an intravenous (IV) catheter was placed
216
and was kept open with saline solution throughout the study visit. A blood sample
217
and GI sample was collected immediately prior to study drug administration and
218
food consumption. The study subjects were randomized to one of two arms for this
219
study: the study drug dosed in the fasting state or the study drug dosed immediately
ACS Paragon Plus Environment
8
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 10 of 32
220
after consuming up to 710 calories (473 mL) of a 55% fat liquid meal to induce the
221
fed state (Pulmocare (pH 6.6), Abbott Nutrition, Lake Forest, IL). Randomization
222
was performed using Research Randomizer software version 4.0. The maximum
223
time allowed to consume the liquid meal was 15 minutes and then the subjects were
224
immediately dosed with ibuprofen.
225
The subject was given an 800 mg tablet of ibuprofen to be swallowed with
226
250 mL of water. After administration of the study drug the subjects did not
227
consume any additional food or water. The study drug, water, and/or Pulmocare
228
were swallowed by the subject and were not administered via the GI catheter. Blood
229
samples were collected at 0 (immediately prior to food consumption and/or study
230
drug administration), 10, 20, 30, and 45 minutes, then at 1, 1.5, 2, 2.5, 3, 4, 5, 6, 7, 8,
231
11 or 12, and approximately 28 hours following study drug administration. Blood
232
samples were added to venous blood collections tubes (K2 EDTA (spray-dried),
233
7.2mg) and plasma was separated from blood samples by centrifugation and stored
234
at -80⁰C.
235
GI fluid samples were collected from available ports by aspiration from
236
individual tubes within the GI catheter. Before collection the contents in the GI
237
catheter remaining from the previous aspiration were collected and discarded. This
238
volume ranged from 3.2 mL for the most distal (jejunal) tube to 1.7 mL for the most
239
proximal (stomach) tube. If the tube was filled with air bubbles then at least 30 cc of
240
the air/fluid mixture (containing no more than 3.2 mL of liquid) was collected and
241
discarded. Collection times included 0 (immediately prior to study drug
242
administration), 15, 30, and 45 minutes, then at 1, 1.5, 2, 2.5, 3, 4, 5, 6, and 7 hours
ACS Paragon Plus Environment
9
Page 11 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
243
following study drug administration. Immediately after collection the samples were
244
pH using a calibrated micro pH electrode (Thermo Scientific Orion pH probe
245
9810BN). Then the GI fluid samples were centrifuged at 21,000 x g for 5 minutes
246
and the supernatant was collected and stored at -80⁰C.
247
At 7 hours following study drug administration, the GI catheter was removed
248
orally from the GI tract and the subject was served a meal. Following the 8 hour
249
blood draw the IV catheter was removed and the remaining blood draws were
250
performed with a butterfly needle and syringe. The subject then returned
251
approximately 28 hours post dosing for the final blood draw.
252
To gain an understanding of intrasubject variability, each subject was asked
253
to complete two GI catheter insertion procedures under the same conditions, either
254
fasting state or fed state. A minimum of 7 days separated each GI catheter insertion
255
procedure. The screening visit was repeated prior to the second study visit if
256
scheduled more than 4 weeks after the first study visit.
257 258 259
LC-MS/MS Analysis of Ibuprofen in GI Fluid and Plasma All samples were analyzed by the Pharmacokinetics Core at the University of
260
Michigan. LC-MS/MS analyses was performed using a Shimadzu HPLC system
261
interfaced to an AB SCIEX QTRAP 5500 mass spectrometer by a TurboV
262
electrospray ionization (ESI) source (Applied Biosystems/MDS Sciex, Toronto,
263
Canada). Ibuprofen-D3 was used as an internal standard (IS) to normalize variation
264
during sample preparation and LC-MS/MS analyses. Chromatographic separation
265
was achieved using a 2.1 x 50 mm, 3.5 µm Agilent ZORBAX Extend-C18 column. The
ACS Paragon Plus Environment
10
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 12 of 32
266
injection volume was 5 µL and the flow rate was kept constantly at 0.4 mL/minutes.
267
Mobile phase A and B were water and acetonitrile, respectively. Both water and
268
acetonitrile contained 0.1% acetic acid (v/v). The flow gradient was initially 98:2
269
v/v of A:B for 0.5 minutes, linearly ramped to 5:95 A:B over 1 minute. To completely
270
wash the column, the gradient was held at 5:95 A:B for 2 minutes and then returned
271
to 98:2 over 0.5 minutes. This condition was held for 3 minutes prior to the injection
272
of another sample. The mass spectrometer was operated at ESI negative ion mode
273
and multiple reaction monitoring (MRM) was used for monitoring the transitions of
274
m/z 205.1→159.1 and m/z 208.2→161.2 for ibuprofen and ibuprofen-D3 (IS),
275
respectively.
276
Protein precipitation with methanol was used to extract ibuprofen from the
277
human plasma. 60 µL of each plasma sample was mixed with 180 µL of methanol
278
containing 500 ng/mL ibuprofen-D3 in a 96-well plate. The mixture was vortexed
279
for 60 seconds at a high speed. The 96-well plate was centrifuged at 3000 x g for 20
280
minutes to precipitate proteins at 4 ⁰C. The clear supernatants were collected and 5
281
µL of the supernatant was injected for LC-MS/MS analysis.
282
Sample preparation of GI fluid was similar to the plasma samples. Due to the
283
inadequate amount of blank GI fluid for preparation of calibration standards and QC
284
samples, the plasma calibration curve was used to quantify ibuprofen in GI fluid. In
285
order to reduce matrix effect, all of the GI fluid samples were diluted 10 fold with
286
blank human plasma before protein precipitation in methanol containing 500
287
ng/mL ibuprofen-D3.
ACS Paragon Plus Environment
11
Page 13 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
288
Molecular Pharmaceutics
Stock solutions of ibuprofen (2 mg/mL) were prepared in methanol. An
289
ibuprofen-D3 (IS) stock solution (5 mg/mL) was prepared in dimethyl sulfoxide. To
290
prepare the calibration standards, the 2 mg/mL ibuprofen stock solution was
291
diluted to 500 µg/mL using methanol, which was spiked with blank human plasma
292
to provide a final ibuprofen plasma concentration of 10 µg/mL. Then serial dilution
293
with the blank human plasma was carried out to provide a series of calibration
294
standards from 2.5-10,000 ng/mL. Quality control (QC) plasma solutions at 5, 25,
295
250, 5000, and 10000 ng/mL were prepared similarly using separately weighed
296
methanol stock solutions of ibuprofen (2 mg/mL). Methanol was used to further
297
dilute the stock ibuprofen-D3 solution to 500 ng/mL for protein precipitation
298
during sample preparation, also to minimize the variation.
299
According to Food and Drug Administration (FDA) guidelines, validation
300
procedures were performed in human plasma and GI fluid diluted with human
301
plasma. These procedures included: (A) specificity and selectivity; (B) recovery and
302
matrix effects at low (0.015 µg/mL), medium (0.1 and 10 µg/mL), and high (35
303
µg/mL) concentrations; (C) calibration curve with a correlation coefficient (r) of
304
more than 0.98; (D) precision and accuracy, with the intra-day and inter-day assay
305
precision and accuracy estimated by analyzing six replicates at three QC levels; (E)
306
stability, with all stability studies conducted at three concentration levels in the
307
biomatrix at room temperature, 4 °C, −20 °C, and −80 °C; and (F) dilution integrity,
308
with experiments carried out with blank biomatrix.
309 310
Pharmacokinetic Analysis and Data Presentation
ACS Paragon Plus Environment
12
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
311
Page 14 of 32
Given the intensive plasma sampling procedure (up to 17 samples/subject),
312
plasma pharmacokinetics were characterized by non-compartmental analyses.
313
These analyses included computation of the area under the curve from time zero to
314
24 hours (AUC0-24) based on the linear-logarithm trapezoidal rule, maximum
315
concentration (Cmax) and time to Cmax (Tmax). Statistical comparisons of these
316
between group comparisons of pharmacokinetic parameters were performed using
317
the Kruskal-Wallis test. Matched comparisons by subjects who had repeated
318
measures was performed using the Wilcoxon-signed rank test. A p value of < 0.05
319
was qualified as statistically significant. Pharmacokinetic and statistical analysis
320
were performed using StataIC version 14.2 (StataCorp, College Station, TX) . All
321
figures were generated with the R 3.2.3 software package utilizing ggplot2 or with
322
Prism 6 (GraphPad Software, Inc.). Average values were shown with the standard
323
error of the mean (SEM). Significance was determined using nonparametric
324
statistical tests.
325 326
Results:
327
Study enrollment numbers and demographics
328
To determine eligibility for this study, 65 subjects were screened and 46 met
329
eligibility criteria. These 46 subjects participated in 60 GI catheter placement
330
procedures. Of these 60 catheter placement studies, 24 were discontinued. There
331
was 1 study visit that was discontinued after study drug administration due to
332
discomfort from the GI catheter. There were 23 study visits that were discontinued
333
prior to study drug administration due to the following reasons: inability to advance
ACS Paragon Plus Environment
13
Page 15 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
334
the GI catheter (n=1), vomiting (n=2), or discomfort caused by the GI catheter after
335
insertion (n=20). One subject experienced an adverse event during the study visit.
336
The subject became hypotensive and reported feeling hot and was clammy to the
337
touch during the study procedures. The subject was immediately placed into the
338
Trendelenburg position while cooling the forehead and neck with ice packs. The
339
subject’s blood pressure returned to baseline after 8 minutes and remained at that
340
level throughout the remainder of the study.
341
The plasma concentration-time information from all 25 subjects that
342
completed the study were reviewed individually and revealed two subjects as
343
extreme values. One subject had a rising concentration time profile over the 8 to 28-
344
hour period with concentrations at the last time-point that were two-fold higher
345
than at the mid-point. Non-adherence with the study protocol such as self-
346
administration of another dose of ibuprofen was assumed and as a precaution
347
samples collected from this subject were not included in subsequent analysis. The
348
second subject had plasma concentrations that were approximately ten-fold lower
349
on two study visits (fed conditions) than values measured in comparable subjects
350
with no reasonable explanation for these observations. Given the small sample size,
351
inclusion of these extreme value data from this subject would contribute to a larger
352
difference in the central tendency estimates of ibuprofen exposure in fed compared
353
to fated subjects (detailed in next section). As a precaution we removed this subject
354
from subsequent data analyses to not skew the effects of food on ibuprofen
355
dissolution and absorption.
ACS Paragon Plus Environment
14
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
356
Page 16 of 32
Details regarding study participants who completed the study procedure and
357
were included in our analysis are included in Table 1. There were a total of 23
358
subjects that completed the study, with 11 subjects returning for an additional study
359
visit (a total of 34 completed study visits) in our analysis. The subjects were
360
primarily white (61%), male (65%) with an average age of 30 years. The subjects
361
had a median [minutes, max] weight of 79 [52, 123] kg and body mass index of 25.7
362
[19.4, 37.7] kg/m2.
363
Table 1: Demographics of study subjects. Study Arm
Number of Subjects
Age (years)
N
Mean ± SD (MinutesMax) 30 ± 9 (18-54)
Total
23
Fed
10
32 ± 9 (22-49)
Fasted
13
29 ± 9 (18-54)
Body Mass Index (BMI) Mean ± SD (MinutesMax) 26.2 ± 4.6 (19.437.7) 27.0 ± 4.5 (21.635.9) 25.7 ± 4.7 (19.435.8)
Sex
Race
Ethnicity
Male
Female
Caucasian
AfricanAmerican
Asian
Hispanic or Latino
2
Not Hispanic or Latino 22
15
8
14
7
6
4
6
4
0
9
1
9
4
8
3
2
13
0
1
364 365 366
Plasma concentration after administration of ibuprofen The mean and standard deviation concentration time profiles from the 23
367
included subjects are displayed in Figure 1 as a semi-logarithm plot and as absolute
368
values by fasted and fed states. Individual concentration-time profiles of subjects by
369
fasted and fed conditions are shown in Figure 2. In both the fasted and fed
370
conditions ibuprofen was detected in the plasma 10 minutes after administration of
371
ibuprofen. As shown in Figures 1 and 2, the Cmax was lower and Tmax longer in the
372
fed versus fasted state.
ACS Paragon Plus Environment
15
Page 17 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
373
374 375
Figure 1. Average plasma concentration vs. time profiles of ibuprofen. Fasted
376
(n=20, green line) and fed (n=14, black line) conditions plotted in A) logarithmic
377
and B) linear scale. Error bars indicate the standard error of the mean (SEM). Data
378
from fasted subjects (n=20) and fed subjects (n=14) are shown.
379
380 381
Figure 2. Individual plasma concentration vs. time profiles of ibuprofen under
382
(A) fasted, and (B) fed conditions. Each line represents an individual subject.
ACS Paragon Plus Environment
16
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 18 of 32
383 384
Fed subjects had a significantly (p= 0.020) lower AUC0-24 value than those in
385
the fasted condition, though this difference was a mean of 5.42% lower. In contrast,
386
the difference in Cmax was 35.2% lower (p=0.025) in the fed versus fasted
387
conditions. This lower Cmax was also associated with a longer Tmax that was a mean
388
of 1.71 hours longer in the fed condition. The specific values and statistical
389
comparison of these parameters are provided in Table 2. To quantify intra-subject
390
variability, we analyzed the AUC0-24 from the 11 subjects that completed two
391
separate study visits under the same treatment conditions. The geometric mean
392
[90% confidence interval] plasma AUC0-24 ratio was 1.056 [0.929, 1.193].
393
Table 2. Plasma pharmacokinetic parameters of ibuprofen (mean +/-
394
standard deviation), including area under the curve from time zero to 24
395
hours (AUC0-24), maximum concentration (Cmax) and time to Cmax (Tmax). Study Arm
Number of Observations
Fasted
20
Fed
14
Statistical Significance
AUC0-24 (µg•hr/mL) 241.888 ± 88.907 229.452 ± 76.879 p = 0.020
Cmax (µg/mL) 58.247 ± 18.400 43.051 ± 14.312 p = 0.025
Tmax (hr) 2.980 ± 1.613 4.694 ± 1.994 p = 0.010
396
Significance was determined using the nonparametric Kruskal-Wallis equality-of-
397
populations rank test.
398 399 400 401
GI pH vales in the GI tract The average pH values in the GI tract are shown in Figure 3. Immediately after feeding the gastric pH increased from acidic values (2.3 ± 0.3) closer to
ACS Paragon Plus Environment
17
Page 19 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
402
neutrality (4.6 ± 0.58). The pH levels gradually decreased until the final
403
measurement 7 hours post dosing, returning to values seen prior to feeding (2.8 ±
404
0.64). After feeding, the pH of the small intestine increased from approximately 5 to
405
6. Fasted subjects had a relatively stable pH compared to the fed subjects
406
throughout the study. The pH values from each subject are shown in Figure 4.
407
Regardless of fed or fasted conditions, the pH in the jejunum showed much less
408
variability than the duodenum and stomach. Both of these regions exhibited large
409
variably between subjects.
410
411 412
Figure 3. Average pH values vs. time profiles throughout the GI tract. A) Fasted
413
and B) Fed study visits are shown. Mid jejunum (black line), Proximal jejunum (red
414
line), Duodenum (green line) and Stomach (blue line). Error bars indicate the
415
standard error of the mean (SEM). Data from fasted subjects (stomach: n=15,
416
duodenum: n=16, proximal jejunum: n=10, mid jejunum: n=12) and fed subjects
417
(stomach: n=13, duodenum: n=11, proximal jejunum: n=6, mid jejunum: n=7) are
418
shown.
419
ACS Paragon Plus Environment
18
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 20 of 32
420 421
Figure 4. Individual pH values vs. time profiles for each subject throughout the
422
GI tract. Each line represents an individual subject.
423 424
In vivo GI concentration of ibuprofen in the GI tract
425
The average concentration of ibuprofen detected in the GI tract is shown in
426
Figure 5 while the ibuprofen concentration in the GI tract for each individual study
427
visit is shown in Figure 6. GI fluid was aspirated 15 minutes post dosing and
428
continued at specified intervals until 7 hours post dosing. As shown in Figure 5,
429
initial samples had a higher concentration of ibuprofen in the stomach for fed
430
subjects while fasted subjects had a higher concentration of ibuprofen in the small
431
intestine. All subjects still had high levels of ibuprofen throughout the GI tract until
432
the last sampling time point, 7 hours post dosing.
433
ACS Paragon Plus Environment
19
Page 21 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
434 435
Figure 5. Average concentration of ibuprofen in luminal GI fluid supernatant
436
throughout the GI tract. A) fasted and B) fed conditions. Mid jejunum (black line),
437
Proximal jejunum (red line), Duodenum (green line) and Stomach (blue line). Error
438
bars indicate the standard error of the mean (SEM). Data from fasted subjects
439
(stomach: n=15, duodenum: n=16, proximal jejunum: n=10, mid jejunum: n=12) and
440
fed subjects (stomach: n=13, duodenum: n=11, proximal jejunum: n=6, mid jejunum:
441
n=6) are shown.
442
ACS Paragon Plus Environment
20
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 22 of 32
443 444
Figure 6. Individual ibuprofen concentrations in plasma and luminal GI fluid
445
supernatant. Each line represents an individual subject.
ACS Paragon Plus Environment
21
Page 23 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
446 447
Figure 7 shows the ibuprofen concentration profiles broken down into each
448
site of the stomach and small intestine. In the stomach under fasted condition, the
449
ibuprofen concentration (19,442 ng/ mL) was detected at 15 minutes post dosing.
450
Surprisingly, the high ibuprofen concentration in stomach remained for 7 hours
451
after dosing (20,055 ng/ mL). In the stomach under fed condition, the ibuprofen
452
concentration (90,637 ng/mL) was detected at 15 minutes post dosing. This was 4.7
453
fold higher than that of fasted condition and this increase of ibuprofen dissolution in
454
the stomach may be due to the higher pH under fed condition.
455
ACS Paragon Plus Environment
22
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
456
Page 24 of 32
Figure 7. Site comparison of the average concentration of ibuprofen in
457
luminal GI fluid supernatant in fed and fasting conditions. A) Stomach, B)
458
Duodenum, C) Proximal Jejunum, and D) Mid Jejunum. Error bars indicate the
459
standard error of the mean (SEM). Data from fasted subjects (stomach: n=15,
460
duodenum: n=16, proximal jejunum: n=10, mid jejunum: n=12) and fed subjects
461
(stomach: n=13, duodenum: n=11, proximal jejunum: n=6, mid jejunum: n=6) are
462
shown.
463 464
It is worth noting that although ibuprofen has higher dissolution in the
465
stomach under fed condition (due to higher pH), the ibuprofen concentration in the
466
duodenum is delayed (due to slow gastric emptying and transit). This delay resulted
467
lower plasma ibuprofen concentration. These data strongly suggest the gastric
468
emptying and transit (at fed state) is dominant to determine the plasma drug
469
concentration.
470 471
Discussion:
472
The goal of this clinical study was to directly measure drug dissolution in the
473
stomach and small intestine of healthy humans in order to better understand the in
474
vivo conditions that affect drug disintegration and dissolution. We chose to evaluate
475
the in vivo drug dissolution and systemic absorption of the BCS Class IIa drug
476
ibuprofen by in vivo sampling of stomach and small intestinal luminal content of
477
fasted and fed subjects. In this study we were able to characterize in vivo the
478
dissolution pattern of ibuprofen through to the mid-jejunum. In addition, this study
ACS Paragon Plus Environment
23
Page 25 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
479
was to determine influence of gastric pH and a fed state on dissolution. These in vivo
480
findings improved our understanding of the luminal profile of this poorly soluble
481
drug and can help to support future models of agents within this class.
482
The effect of food on the pharmacokinetics of immediate release NSAIDs has
483
recently been reviewed10. Having increased plasma levels of ibuprofen results in
484
increased analgesic effect of the drug11, however consumption of food can decrease
485
plasma levels of ibuprofen10. Ibuprofen is generally taken with food to improve
486
tolerability therefore we sought to understand the effect of food on in vivo drug
487
disintegration and dissolution of ibuprofen. Our results were consistent with
488
previous studies10 showing an overall decrease in the Cmax, delay of the Tmax, and
489
overall decrease in the AUC0-24 in the plasma of fed subjects compared to fasted
490
subjects. By utilizing direct in vivo sampling of the GI tract we were able to detect
491
ibuprofen 15 minutes after dosing in both fed and fasted conditions. In fasted
492
subjects ibuprofen was readily detected in the small intestine, which reflected in
493
higher plasma concentrations compared to fed subjects. There were high
494
concentrations of ibuprofen in the stomachs of fed subjects compared to fasted
495
subjects. The increase in pH increased drug dissolution in the stomach, however,
496
that did not increase the rate of systemic drug absorption. Ibuprofen is thought to
497
be poorly absorbed in the stomach of humans, with the small intestine being the
498
main site of absorption12. Our data suggests that feeding increases the stomach pH
499
which in turn increases drug dissolution, however this does not result in higher
500
plasma concentrations. The fed condition likely delay of gastric emptying and transit
501
of drug from stomach to duodenum which correlated with lower Cmax, lower AUC0-24,
ACS Paragon Plus Environment
24
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 26 of 32
502
and longer Tmax. These data strongly suggest that the GI transit a major determinant
503
for lower plasma drug concentration under fed state.
504
Our results, as well as results from others13, 14, show that there is remarkable
505
intersubject variability in the pH of the gastrointestinal tract. The low pH in the
506
stomach below the pKa of 4.4 for ibuprofen15, 16 correlates with low measurable
507
concentrations in this part of the GI tract. Consumption of food that leads to an
508
initial increase in stomach pH also leads to measurable stomach concentrations of
509
ibuprofen. However, food slows the rate of absorption leading to a lower Cmax and
510
longer Tmax but marginally alters the extent of absorption (as indicated by a similar
511
AUC0-24). This alteration in the concentration-time profile relevant for ibuprofen
512
because the analgesic effects of this drug are related to increased plasma levels of
513
the drug11. The observed extension in the Tmax by approximately 1.7 hours also
514
implies an expected delay in the therapeutic effects of this drug.
515
A major unexpected finding of this work was the prolonged high levels of
516
ibuprofen in the GI tract. Our results show that ibuprofen was detected in the GI
517
tract over the course of the seven hours of sampling. Although this was limited to 7
518
hours based on our sampling schema, it is likely that some subjects may have local
519
concentrations in the GI tract for longer periods of time. The implications of
520
prolonged GI retention of ibuprofen have not been previously characterized.
521
Previously, the transit in stomach is estimated from 30 minutes to 2 hours and
522
transit time in small intestine is average of 3 hours and these estimates were used in
523
drug absorption model prediction. The high drug concentration in the stomach and
524
small intestine for 7 hours may challenge these previous assumptions in drug
ACS Paragon Plus Environment
25
Page 27 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
525
absorption prediction. Better models may need to be developed for better in vitro
526
and in vivo correlation and oral absorption prediction.
527
In addition, it is known that prolonged use of NSAIDs are associated with an
528
increase in gastroduodenal ulceration. From a theoretical perspective, sustained
529
exposure of local GI tissue to ibuprofen may contribute to the peptic ulcer disease
530
associated with this drug. Our results suggest that there is prolonged exposure to
531
ibuprofen in the GI tract, especially after taking ibuprofen with food. Additionally,
532
food increases the initial ibuprofen convention approximately 5 fold compared to
533
fasted subjects 15 minutes after dosing. Our findings suggest we may need to
534
reconsider taking ibuprofen with food. While taking with food might alleviate acute
535
symptoms of GI discomfort it may lead to long term consequences by delaying
536
gastric emptying and leading to prolonged exposure of the stomach lining to
537
ibuprofen.
538
One potential limitation for this study is that with any aspiration catheter going
539
past the pylorus in the stomach there is a possibility of altering gastric emptying by
540
altering how the pylorus opens and closes. Additionally, the presence of a catheter
541
could have an effect on duodenogastric reflux and this in turn could affect drug
542
dissolution and absorption. However, this was examined in work by Muller-Lissner
543
et al. using a catheter of the similar size (3.0 mm compared to our 3.3 mm catheter
544
diameter)17. They found no effect on gastric emptying or duodenogastric reflux
545
when the catheter was placed past the pylorus. No effect of the catheter was found
546
in both fed and fasted conditions. Therefore, the method of using an aspiration
ACS Paragon Plus Environment
26
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 28 of 32
547
catheter to study drug dissolution and absorption should be similar compared to the
548
catheter no being present.
549
Another potential limitation is that the use of aspiration catheters can be
550
considered uncomfortable to the subject due to the presence of a foreign object
551
placed down the subject’s throat. This caused generalized anxiety and
552
uncomfortable feeling in the subject’s throat. We did have 36 out of 60 subjects
553
complete the entire study that had the tube placed for approximately 15 hours. This
554
success rate was similar to a previous study using a similar multi-lumen catheter
555
where the tube was placed for a similar length of time14. While the success rate is
556
lower than other studies5, this could be due to the length of time the tube was
557
placed. For example, work from Hens et al. had a higher success rate for the study
558
but the tube was in place for much less time (approximately 4 hours)5. The
559
generalized anxiety of having the tube placed for 15 hours in our study may have
560
decreased the success rate. However, having the tube placed for this long allowed us
561
to obtain manometry data as well has aspirate fluid for 7 hours after dosing that
562
resulted in a very large data set.
563
The use on aspiration catheters allows us to better understand the in vivo
564
conditions involved in to study drug dissolution and absorption. In this study we
565
presented the data obtained for the gastric and small intestinal pH as well as the
566
concentrations of ibuprofen in the GI tract and plasma. Further analysis of the data
567
set obtained in this clinical study is described in the manuscript by Hens et al.18. In
568
this work, Hens et al. further described how ibuprofen concentration in the stomach
569
and small intestine correlate to buffer capacity as well as motility. Additionally Hens
ACS Paragon Plus Environment
27
Page 29 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
570
et al. looks at the effect of pH and drug dissolution by analyzing the levels of
571
undissolved ibuprofen in the GI tract.
572
The ability to directly sample small intestinal luminal samples allowed us to
573
follow drug dissolution in vivo. The use of multi-lumen catheters to aspirate GI fluid
574
to study drug dissolution has been pioneered over 30 years ago, however relatively
575
few studies have been performed since19 (reviewed by Hens20 and Brouwers21). In
576
the past few years multiple groups have begun to utilize this technique to aspirate
577
samples from the stomach and GI tract5, 14, 20, 22. Because of this we are beginning to
578
get a better understanding of the complex GI physiological parameters involved in
579
drug dissolution and absorption. A multi-lumen GI catheter is a powerful tool to be
580
able to independently sample multiple sites in the GI tract to compare regional and
581
temporal drug disintegration and dissolution. Future work is needed to connect
582
motility, gastric emptying, buffer capacity, viscosity to better understand in vivo
583
drug dissolution and absorption. We hope the in vivo results obtained in this study
584
can be used to validate in vitro dissolution methodologies in order to support future
585
computational and mathematical modeling efforts. This will aid in the development
586
of an oral drug product optimization process that can be applied to future drugs in
587
order to maximize oral drug safety and efficacy.
588 589 590
Conclusion: In this study we used a novel multi-lumen catheter with the ability to aspirate
591
luminal GI fluid from the stomach and small intestine. Using this catheter, we were
592
able to identify that ibuprofen remains in stomach and small intestine for 7 hours.
ACS Paragon Plus Environment
28
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Page 30 of 32
593
The fed state delayed transit of ibuprofen into the duodenum (presumably due to a
594
delay in gastric emptying) compared to the fasted state. The fed state increased drug
595
dissolution in stomach (presumably due to increase of pH in the fed state) compared
596
to the fasted state however this did not result in an overall increase in plasma levels
597
of ibuprofen.
598 599 600
Acknowledgments: This research was funded by FDA grant HHSF223201310144C. Clinical
601
samples collected with help from Michigan Institute for Clinical & Health Research
602
(MICHR) NIH grant UL1TR000433. We also thank Bart Hens for thoughtful
603
discussion of this manuscript.
604
ACS Paragon Plus Environment
29
Page 31 of 32
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Molecular Pharmaceutics
605
References:
606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648
1. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharmaceutical research 1995, 12, (3), 41320. 2. Tsume, Y.; Mudie, D. M.; Langguth, P.; Amidon, G. E.; Amidon, G. L. The Biopharmaceutics Classification System: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci 2014, 57, 152-63. 3. Van Den Abeele, J.; Brouwers, J.; Mattheus, R.; Tack, J.; Augustijns, P. Gastrointestinal Behavior of Weakly Acidic BCS Class II Drugs in Man--Case Study of Diclofenac Potassium. Journal of pharmaceutical sciences 2016, 105, (2), 687-96. 4. Van Den Abeele, J.; Schilderink, R.; Schneider, F.; Mols, R.; Minekus, M.; Weitschies, W.; Brouwers, J.; Tack, J.; Augustijns, P. Gastrointestinal and Systemic Disposition of Diclofenac under Fasted and Fed State Conditions Supporting the Evaluation of in Vitro Predictive Tools. Mol Pharm 2017. 5. Hens, B.; Corsetti, M.; Brouwers, J.; Augustijns, P. Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion. Journal of pharmaceutical sciences 2016, 105, (9), 2904-12. 6. Rainsford, K. D. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology 2009, 17, (6), 275-342. 7. Davies, N. M. Clinical pharmacokinetics of ibuprofen. The first 30 years. Clin Pharmacokinet 1998, 34, (2), 101-54. 8. Wolfe, M. M.; Lichtenstein, D. R.; Singh, G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. The New England journal of medicine 1999, 340, (24), 1888-99. 9. Singh, B. N. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet 1999, 37, (3), 213-55. 10. Moore, R. A.; Derry, S.; Wiffen, P. J.; Straube, S. Effects of food on pharmacokinetics of immediate release oral formulations of aspirin, dipyrone, paracetamol and NSAIDs - a systematic review. Br J Clin Pharmacol 2015, 80, (3), 381-8. 11. Laska, E. M.; Sunshine, A.; Marrero, I.; Olson, N.; Siegel, C.; McCormick, N. The correlation between blood levels of ibuprofen and clinical analgesic response. Clin Pharmacol Ther 1986, 40, (1), 1-7. 12. Adams, S. S.; Bough, R. G.; Cliffe, E. E.; Lessel, B.; Mills, R. F. Absorption, distribution and toxicity of ibuprofen. Toxicol Appl Pharmacol 1969, 15, (2), 310-30. 13. Koziolek, M.; Grimm, M.; Becker, D.; Iordanov, V.; Zou, H.; Shimizu, J.; Wanke, C.; Garbacz, G.; Weitschies, W. Investigation of pH and Temperature Profiles in the GI Tract of Fasted Human Subjects Using the Intellicap((R)) System. Journal of pharmaceutical sciences 2015, 104, (9), 2855-63. 14. Yu, A.; Baker, J. R.; Fioritto, A. F.; Wang, Y.; Luo, R.; Li, S.; Wen, B.; Bly, M.; Tsume, Y.; Koenigsknecht, M. J.; Zhang, X.; Lionberger, R.; Amidon, G. L.; Hasler, W. L.; Sun, D. Measurement of in vivo Gastrointestinal Release and Dissolution of Three
ACS Paragon Plus Environment
30
Molecular Pharmaceutics
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683
Page 32 of 32
Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract. Mol Pharm 2017, 14, (2), 345-358. 15. Levis, K. A.; Lane, M. E.; Corrigan, O. I. Effect of buffer media composition on the solubility and effective permeability coefficient of ibuprofen. Int J Pharm 2003, 253, (1-2), 49-59. 16. Krieg, B. J.; Taghavi, S. M.; Amidon, G. L.; Amidon, G. E. In Vivo Predictive Dissolution: Comparing the Effect of Bicarbonate and Phosphate Buffer on the Dissolution of Weak Acids and Weak Bases. Journal of pharmaceutical sciences 2015, 104, (9), 2894-904. 17. Muller-Lissner, S. A.; Fimmel, C. J.; Will, N.; Muller-Duysing, W.; Heinzel, F.; Blum, A. L. Effect of gastric and transpyloric tubes on gastric emptying and duodenogastric reflux. Gastroenterology 1982, 83, (6), 1276-9. 18. Hens, B.; Tsume, Y.; Bermejo, M.; Paixao, P.; Koenigsknecht, M. J.; Baker, J. R.; Hasler, W. L.; Lionberger, R.; Fan, J.; Dickens, J.; Shedden, K.; Wen, B.; Wysocki, J.; Loebenberg, R.; Lee, A.; Frances, A.; Amidon, G.; Yu, A.; Benninghoff, G.; Salehi, N.; Talattof, A.; Sun, D.; Amidon, G. L. Low Buffer Capacity and Alternating Motility along the Human Gastrointestinal Tract: Implications for in Vivo Dissolution and Absorption of Ionizable Drugs. Mol Pharm 2017. 19. Jobin, G.; Cortot, A.; Godbillon, J.; Duval, M.; Schoeller, J. P.; Hirtz, J.; Bernier, J. J. Investigation of drug absorption from the gastrointestinal tract of man. I. Metoprolol in the stomach, duodenum and jejunum. Br J Clin Pharmacol 1985, 19 Suppl 2, 97S-105S. 20. Hens, B.; Corsetti, M.; Spiller, R.; Marciani, L.; Vanuytsel, T.; Tack, J.; Talattof, A.; Amidon, G. L.; Koziolek, M.; Weitschies, W.; Wilson, C. G.; Bennink, R. J.; Brouwers, J.; Augustijns, P. Exploring gastrointestinal variables affecting drug and formulation behavior: Methodologies, challenges and opportunities. Int J Pharm 2017, 519, (12), 79-97. 21. Brouwers, J.; Augustijns, P. Resolving intraluminal drug and formulation behavior: Gastrointestinal concentration profiling in humans. Eur J Pharm Sci 2014, 61, 2-10. 22. Litou, C.; Vertzoni, M.; Goumas, C.; Vasdekis, V.; Xu, W.; Kesisoglou, F.; Reppas, C. Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug - Drug Interaction Studies. Pharmaceutical research 2016, 33, (6), 1399-412.
ACS Paragon Plus Environment
31